Impairment of Nrf2 signalling or reduced Nrf2 activity has been observed in various pathological conditions associated with oxidative stress, including neurodegenerative diseases (Osama et al., 2020), cardiovascular diseases (Silva-Palacios et al., 2016), metabolic disorders (Zhang et al., 2015), and cancer (Schmidlin et al., 2021). This evidence concerns the gene NFE2L2 and metabolic disease.